SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - SAB Biotherapeutics, Inc. is advancing its clinical-stage biopharmaceutical development focused on human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes and other autoimmune diseases, with a significant presentation scheduled at the J.P. Morgan Healthcare Conference [1] Company Overview - SAB Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing multi-specific, high-potency human immunoglobulin G (hIgG) aimed at treating and preventing immune and autoimmune disorders [3] - The lead candidate, SAB-142, targets autoimmune type 1 diabetes (T1D) with a therapeutic approach that seeks to modify the disease by delaying onset and potentially preventing progression in Stage 3 T1D patients [3] - The company utilizes advanced genetic engineering and antibody science to create a proprietary technology that can generate novel therapeutic candidates without relying on human donors or convalescent plasma [3] - SAB Biotherapeutics has optimized genetic engineering through the development of transchromosomic cattle (Tc-Bovine™) to produce hIgG, enabling the generation of a diverse range of specifically targeted, high-potency hIgGs to address serious unmet medical needs [3]